Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;99(10):2045-2049.
doi: 10.1016/j.apmr.2018.05.029. Epub 2018 Jun 30.

Diagnostic and Clinical Utility of the GAD-2 for Screening Anxiety Symptoms in Individuals With Multiple Sclerosis

Abbey J Hughes  1 , Katherine M Dunn  2 , Trisha Chaffee  3 , Jagriti Jackie Bhattarai  3 , Meghan Beier  3
Affiliations

Diagnostic and Clinical Utility of the GAD-2 for Screening Anxiety Symptoms in Individuals With Multiple Sclerosis

Abbey J Hughes et al. Arch Phys Med Rehabil. 2018 Oct.

Abstract

Objective: To assess the diagnostic and clinical utility of the 2-item Generalized Anxiety Disorder Scale (GAD-2) for screening anxiety symptoms in individuals with multiple sclerosis (MS).

Design: Cross-sectional.

Setting: University-affiliated MS neurology and rehabilitation center.

Participants: The sample comprised adults (N=99) (ages 19-72; mean ± SD=46.2±13.0; 75% women) with a physician-confirmed MS diagnosis who were receiving care in a university-affiliated MS center. Disease durations ranged from 1 to 37 years (mean ± SD=10.7±8.4).

Interventions: Not applicable.

Main outcome measures: Participants completed the 7-item Generalized Anxiety Disorder Scale (GAD-7) and GAD-2. Internal consistency was calculated for both measures. Area under the receiver operating characteristics curve (AUC), the 95% confidence interval for the AUC, and Youden's J were calculated to determine the optimal GAD-2 cutoff score for identifying clinically significant anxiety symptoms, as defined by the previously validated GAD-7 cutoff score of ≥8.

Results: Internal consistency was excellent for the GAD-7 (Cronbach α=.91) and acceptable for the GAD-2 (α=.77), and the measures were highly correlated (r=.94). The GAD-2 had excellent overall accuracy for identifying clinically significant anxiety symptoms (AUC=0.97; 95% confidence interval, 0.94-1.00). A GAD-2 cutoff score of ≥3 provided an optimal balance of good sensitivity (0.87) and excellent specificity (0.92) for detecting clinically significant anxiety symptoms. Alternatively, a cutoff score of ≥2 provided excellent sensitivity (1.00) and fair specificity (0.76).

Conclusions: The GAD-2 is a clinically useful and psychometrically valid tool for screening anxiety symptoms in MS rehabilitation and neurology care settings. Importantly, this tool has the potential to identify individuals with MS who are at risk for anxiety disorders and who may benefit from rehabilitation psychology interventions to ultimately improve functioning and quality of life.

Keywords: Anxiety; Multiple sclerosis; Rehabilitation; Screening.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

We certify that no party having a direct interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which they are associated and we certify that all financial and material support for this research and work are clearly identified in the title page of the manuscript.

Figures

Figure 1.
Figure 1.
Receiver operating characteristic (ROC) curve for GAD-2 scores for clinically significant anxiety symptoms (GAD-7 ≥ 8). Area under the ROC curve = 0.97 (95% CI: 0.94 – 1.00).
See this image and copyright information in PMC

References

    1. Mitchell AJ, Benito-León J, González J-MM, Rivera-Navarro J. Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. The Lancet Neurology. 2005;4(9):556–566. - PubMed
    1. Askari F, Ghajarzadeh M, Mohammadifar M, Azimi A, Sahraian MA, Owji M. Anxiety in patients with multiple sclerosis: association with disability, depression, disease type and sex. Acta Med Iran. 2014;52(12):889–892. - PubMed
    1. Theaudin M, Romero K, Feinstein A. In multiple sclerosis anxiety, not depression, is related to gender. Mult Scler. 2016;22(2):239–244. - PubMed
    1. Garfield AC, Lincoln NB. Factors affecting anxiety in multiple sclerosis. Disabil Rehabil. 2012;34(24):2047–2052. - PubMed
    1. Feinstein A, O’Connor P, Gray T, Feinstein K. The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult Scler. 1999;5(5):323–326. - PubMed

Publication types